Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval.
Abstract
Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB) [...].
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | bladder
|
scispacy | 1 | ||
| 약물 | BotulinumtoxinA
|
scispacy | 1 | ||
| 약물 | Urinary
|
scispacy | 1 | ||
| 약물 | Food
|
scispacy | 1 | ||
| 약물 | OAB
→ overactive bladder
|
scispacy | 1 | ||
| 질환 | Hyperactive Urinary Tract Dysfunction
|
scispacy | 1 | ||
| 질환 | idiopathic overactive bladder
|
scispacy | 1 | ||
| 질환 | BotulinumtoxinA
|
scispacy | 1 |
MeSH Terms
Humans; Botulinum Toxins, Type A; Urinary Bladder, Overactive; Drug Approval; Urinary Bladder, Neurogenic; Neuromuscular Agents
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.